HC Wainwright Issues Positive Estimate for ABEO Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Analysts at HC Wainwright increased their Q2 2026 earnings per share estimates for Abeona Therapeutics in a note issued to investors on Thursday, May 14th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($0.28) per share for the quarter, up from their previous estimate of ($0.33). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($0.74) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.09) EPS, Q1 2027 earnings at ($0.22) EPS and FY2027 earnings at ($0.48) EPS.

Several other brokerages have also recently issued reports on ABEO. Wall Street Zen upgraded Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Stifel Nicolaus set a $17.00 target price on Abeona Therapeutics in a research note on Tuesday, March 17th. Oppenheimer restated an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $19.00.

Abeona Therapeutics Trading Down 2.2%

Shares of ABEO stock opened at $5.37 on Tuesday. The company has a current ratio of 5.89, a quick ratio of 5.70 and a debt-to-equity ratio of 0.03. The stock has a market cap of $306.04 million, a P/E ratio of 5.54 and a beta of 1.35. The stock has a 50 day simple moving average of $5.10 and a 200 day simple moving average of $5.04. Abeona Therapeutics has a 1 year low of $4.00 and a 1 year high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.03. The company had revenue of $8.72 million during the quarter, compared to the consensus estimate of $4.57 million.

Insider Buying and Selling at Abeona Therapeutics

In other Abeona Therapeutics news, Director Eric Crombez sold 26,143 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $5.53, for a total transaction of $144,570.79. Following the completion of the sale, the director directly owned 37,313 shares in the company, valued at $206,340.89. This represents a 41.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Madhav Vasanthavada sold 5,548 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $5.96, for a total value of $33,066.08. Following the sale, the insider owned 313,071 shares of the company’s stock, valued at $1,865,903.16. The trade was a 1.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 5.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its stake in shares of Abeona Therapeutics by 49.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,450 shares of the biopharmaceutical company’s stock valued at $954,000 after acquiring an additional 66,422 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Abeona Therapeutics by 129.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock valued at $6,282,000 after acquiring an additional 623,243 shares during the last quarter. Creative Planning lifted its stake in shares of Abeona Therapeutics by 43.0% in the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 4,305 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Abeona Therapeutics by 255.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 831,132 shares of the biopharmaceutical company’s stock valued at $4,721,000 after acquiring an additional 597,373 shares during the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Abeona Therapeutics in the 2nd quarter valued at $27,000. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.